Virtual Library

Start Your Search

K. Watanabe



Author of

  • +

    P1.06 - Poster Session with Presenters Present (ID 458)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P1.06-019 - The Possibility of the Additional Local Therapy to Systemic Chemotherapy in Advanced Lung Cancer Cases with Multiple Metastases (ID 4488)

      14:30 - 15:45  |  Author(s): K. Watanabe

      • Abstract

      Background:
      In stage IV non-small cell lung cancer (NSCLC) patients with multiple metastases, a various pattern of disease progression is observed, including the growth of only primary site, the growth of only pre-existing metastatic site, or the appearance of new metastatic site. The aim of our study is to evaluate the detailed recurrence pattern in patients with stage IV NSCLC, and is also to evaluate whether a specific patient’s population exists whose disease progression is well controlled by the additional local therapy, such as surgery or radiotherapy to the primary or pre-existing metastatic site, during or after the systemic chemotherapy.

      Methods:
      NSCLC patients in stage IV admitted to our hospital from 2012 to 2014 were examined retrospectively. The recurrence pattern was classified into the following groups; the growth of primary site, the growth of pre-existing metastatic site, or the appearance of new metastatic site. Furthermore, progression-free survival (PFS), overall survival (OS), and new lesion-free survival (NFS) of these groups were examined, respectively.

      Results:
      Patients treated with chemotherapy for stage IV NSCLC were 114 cases. The median age was 70 years old, and male was 74 cases. The number of platinum-based combination regimen was 71 cases, monotherapy was 16 cases, epidermal growth factor receptor tyrosine kinase inhibitor was 25 cases, crizotinib was two cases. In the first-line chemotherapy, median PFS, median OS and median NFS in all patients were 172 days, 417 days and 270 days. Median PFS, median OS and median NFS in patients for the growth of primary site were 235 days, not reached and not reached. Median PFS, median OS and median NFS in patients for the growth of pre-existing metastatic site were 171 days, 250 days and 205 days. Median PFS, median OS and median NFS in patients for the appearance of new metastatic site were 149 days, 423 days and 149 days.

      Conclusion:
      The prognosis of the appearance of new metastatic site group seems to be worse than the growth of primary site group in the pattern of disease progression in the first-line chemotherapy. And the prognosis of the growth of pre-existing metastatic site group seems to be worse than the appearance of new metastatic site group. In the stage IV NSCLC therapy, there is a possibility that the treatment outcomes will be improved according to well controlled the pre-existing metastatic site by the additional local therapy.